COMMD10

Across TCGA pan-cancer cohorts, COMMD10 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of COMMD10’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where COMMD10 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types COMMD10 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where COMMD10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in COMMD10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.295	<.001	11	view →
PDAC	All	III,IV	−0.398	<.001	10	view →
LUAD	Male	III,IV	−0.340	<.001	9	view →
LSCC	Male	II,III,IV	−0.438	<.001	8	view →
HNSC	Male	II,III,IV	−0.280	<.001	8	view →
COAD	Male	II,III,IV	−0.199	.015	3	view →
OV	All	All	+0.230	.046	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

COMMD10–CCRCC

Open the CCRCC breakdown →